significant differences. The proportions of early mortality (0.3% vs. 0.1%; RR: 3,) and overall complications (5.1% vs. 6.3%, RR: 0.80, 95%CI: 0.46-1.38) was low and with no statistically significant differences in OPG vs. IPG patients. Additionally, the RRs for any of the reported specific complications (Table 1) were not significantly different across both groups.
INTRODUCTION AND OBJECTIVES: The Expanded Prostate
Cancer Index short form (EPIC-26) is a validated questionnaire for measuring health-related quality-of-life in men with prostate cancer. Responses to the 26 individual questions are aggregated into 5 domains, with domain scores reported as a measure of patient function. However, the relationship between domain score and specific functional outcomes remains unclear, leading to potential confusion about expectations after treatment. For instance, what does a sexual function domain score of 80 actually mean with regard to a patient being able to obtain an erection sufficient for intercourse? Resultantly, we sought to clarify the relationship between domain scores and individual questions reflecting clinically relevant outcomes.
METHODS: Utilizing data obtained from the Comparative Effectiveness Analysis of Surgery and Radiation (CEASAR) Study, a multicenter, prospective study of men diagnosed with localized prostate cancer in 2011 to 2012, we analyzed the EPIC-26 from 2,138 men at 3 years of follow-up who were treated with either radical prostatectomy, radiotherapy, or active surveillance. We dichotomized every EPIC-26 questionnaire item into its best possible outcome (best vs. any other response) and assessed the percentage of men at each domain score who obtained the best result.
RESULTS: Figure 1 highlights the relationship between domain scores and individual items and demonstrates the domain score below which optimal functional outcomes are less likely. For example, a score of 80 on the sexual function domain corresponded to 96% of men reporting an erection sufficient for intercourse whereas at 40, only 12% of men reported adequate erections. Meanwhile, at a score of 95 on the urinary incontinence domain, 100% of patients reported no leakage vs. 0% at a score of 50. Similarly, at a score of 95, 100% of patients reported no pads vs. only 30% at a score of 50.
CONCLUSIONS: Our findings show a novel way to interpret EPIC-26 domain scores and understand clinically meaningful differences. Our results suggest a particular change in domain score may have a differential impact on clinically relevant functional outcomes depending on the baseline domain score. This information may be valuable when counseling men preoperatively on treatment options.
Source of Funding: None

MP44-17 A NATIONAL SURVEY OF RADIATION ONCOLOGISTS AND UROLOGISTS ON PREDICTION TOOLS AND NOMOGRAMS FOR LOCALIZED PROSTATE CANCER
Boris Gershman, Providence, RI; Paul Maroni, Denver, CO; Jon Tilburt, Rochester, MN; Robert Volk, PhD, Houston, TX; Badrinath Konety, MD, Minneapolis, MN; Alexander Kutikov, MD, Marc Smaldone, Marc Smaldone, Philadelphia, PA; Victor Chen, Cleveland, OH; Simon Kim*, Denver, CO INTRODUCTION AND OBJECTIVES: Integration of prediction tools for prostate cancer (PCa) is essential to high quality treatment decisions and shared decision-making. Yet, little is known about the degree of confidence in existing tools and whether they are used in clinical practice from radiation oncologists (RO) and urologists (URO). Herein, we performed a national survey of specialists about perceived attitudes and use of prediction tools.
METHODS: In 2017, we surveyed 940 URO and 911 RO to query their confidence in and use of the D'Amico criteria, Kattan Nomogram, and CAPRA score from a 4-wave mailing. The statistical analysis involved bivariate association and multivariable logistic regression analyses to identify physician characteristics associated with survey response and use of active surveillance (AS) for lowrisk PCa.
RESULTS: Overall, 691 (37.3%) specialists completed the surveys with similar response rates from RO and URO (35.7% vs. 38.7%; p[.18 ). Two thirds (Range: 65.6% -68.4%) of respondents reported being "somewhat confident", but only a fifth selected "very confident" for each prediction tool (18.0% -20.1%). 19.1% of specialists in the survey reported not using any prediction tools in clinical practice, which was higher amongst URO than RO (23.9% vs. 13.4%; p < 0.001). Lack of using prediction tools was also associated with low use of AS (<5%) in their low-risk PCa patients (OR: 2.47; p [ 0.01).
CONCLUSIONS: While a majority of RO and URO view existing prediction tools for localized PCa with some degree of confidence, a fifth of specialists reported not using any such tools in clinical practice. Vol. 201, No. 4S, Supplement, Saturday, May 4, 2019 THE JOURNAL OF UROLOGY Ò e635
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